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Inflammatory bowel disease (IBD) includes a set of pathologies that result from a deregu-
lated immune response that may affect any portion of the gastrointestinal tract. The most 
prevalent and defined forms of IBD are Crohn’s disease and ulcerative colitis. Although 
the etiology of IBD is not well defined, it has been suggested that environmental and 
genetic factors contribute to disease development and that the interaction between these 
two factors can trigger the pathology. Diet, medication use, vitamin D status, smoking, 
and bacterial infections have been proposed to influence or contribute to the onset or 
development of the disease in susceptible individuals. The infection with pathogenic 
bacteria is a key factor that can influence the development and severity of this disease. 
Here, we present a comprehensive review of studies performed in human and mice 
susceptible to IBD, which supports the notion that infection with bacterial pathogens, 
such as Salmonella, could promote the onset of IBD due to permanent changes in the 
intestinal microbiota, disruption of the epithelial barrier and alterations of the intestinal 
immune response after infection.
Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, gut microbiota, Salmonella enterica 
serovar Typhimurium, innate immune response, virulence factors
iNTRODUCTiON
Inflammatory bowel disease (IBD) is defined as a set of pathologies that exhibit a progressive and 
chronic phenotype, where the intestinal immune response and the normal gut microbiota are altered 
(1). IBD usually begins in adolescence and persists lifelong (2). The symptoms of these inflammatory 
disease are not only limited to the gastrointestinal level but also produces systemic complications 
such as fever, weight loss, delayed sexual maturation and growth, among others. Further, extraintes-
tinal diseases can be associated with IBD, including arthritis (3). The most common clinical mani-
festations of IBD are Crohn’s disease (CD) and ulcerative colitis (UC) (2). CD, a manifestation that 
affects females in a greater proportion, is characterized by a chronic and transmural inflammation, 
specifically at the colon and small intestine. However, inflammatory lesion during CD can be found 
at any section of the gastrointestinal tract, from the mouth to the anus (4). These lesions can affect 
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all layers of the gastrointestinal tract, producing strictures and 
fistulae (5, 6). CD mostly affects the young population, with a 
peak of incidence in the early adulthood (between 20 and 30 years 
old). UC, on the other hand, is a manifestation more common 
in males and only affects the superficial layer of the colon, with 
a continuous inflammation comprising from the rectus to vari-
able distances along the intestine (6, 7). The incidence of IBD is 
higher in industrialized or westernized regions, such as the 
United States and Northern and Western Europe, and it is mild 
in South America and Africa (8). The same pattern is observed 
in urban and rural areas, indicating that industrialization can be 
considered as an etiological factor for major incidence of IBD (7, 
8). Additional factors, such as environmental and genetic factors, 
interact to determine the onset and development of disease.
Different studies have shown the correlation between environ-
mental and genetic factors that could lead to a dysfunction of 
the intestinal epithelial barrier, with a consequent deregulation 
in the function of the mucosal immune cells. These alterations 
lead either to an inappropriate recognition of the gut microbiota 
or an increased susceptibility to infections (7, 9). Moreover, 
environmental factors can differentially affect predisposition of 
individuals, by increasing their susceptibility to develop IBD 
(10). The increase in the incidence of IBD has been associated 
with several factors common to modern lifestyle, such as use of 
antibiotics, vaccines, contraceptives, vitamin D status, and better 
hygiene. Further, changes associated with westernization, such 
as high consumption of fats, refined sugar, and carbohydrates, 
have also been implicated in the incidence increase for these 
diseases during the last decades (11). According to previously 
observed associations between the consumption of some food 
and incidence of UC or CD, it is presumed that the diet could 
induce changes in the microbiota composition and in the cellular 
adhesion to the intestinal barrier (12), which could in turn lead 
the development of IBD (11).
Inflammatory bowel disease is a disease highly influenced by 
genetic factors. Several genetic mutations and polymorphism 
have been described in both UC and CD (13–15). Interestingly, 
some of the polymorphisms associated with IBD locate in genes 
encoding proteins involved in bacteria recognition, degradation, 
or translocation through the intestinal epithelial barrier. For 
instance, it has been described that in both UC and CD patients 
there are polymorphisms in genes associated with the Th1/Th17 
pathway [il23r (16), il12b (17), or stat3 (17) genes]; autophagy 
[atg16l1 (18), irmg (19), and nod2 (20)]; and epithelial barrier 
[jak2 (13) and il-10 (14)]. These mutations affect the capacity 
of the innate immune cells to handle intracellular bacteria due 
to an aberrant autophagy process. These alterations result in a 
response unable to control systemic bacteria spread, which 
predisposes the host to an increased pathogen colonization and 
an enhanced susceptibility to these diseases (21). Another gene 
involved in CD is nod2, which encodes the nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2). This gene 
is in chromosome 16 and encodes an intracellular receptor for the 
muramyl dipeptide (MDP), a component of bacterial cell wall. 
When this gene is silenced, it is observed that an aberrant IL-1β 
production occurs in response to bacterial endotoxins, which 
leads to an impaired early immune response (22, 23). Mutation 
in nod2 also affects the function of Paneth cells, diminishing the 
production of α-defensin, an antimicrobial peptide secreted by 
this type of cells (24, 25). Variants of this gene, combined with 
polymorphisms in tlr9 or atg16l1, increase the risk of suffering 
IBD (22). The atg16l1 gene encodes a key protein in the process 
of autophagy (9), which is required for a proper innate immune 
response against microorganisms. Mice ATG16L1HM, which carry 
a disruption of the atg16l1 gene with a concomitant decreased 
protein level, display abnormal Paneth cells function due to a 
defect of the granule exocytosis pathway. Such a phenotype can 
also be observed in CD patients. In consequence, the secretion of 
lysozyme is altered, and the expression of genes involved in injury 
response is increased (26). These data indicate that Paneth cells 
have a unique sensitivity to autophagy gene disruption, which 
lead to endoplasmic reticulum stress in the intestinal epithelium. 
Thus, the autophagy process could have a specific role in these 
cells, as it seen in CD patients (26–28). In another study, research-
ers found that patients with variants in nod2 and/or atg16l1 genes 
display an increased secretion of TNF-α in response to bacterial 
translocation through the intestinal epithelial barrier, which is 
directly related to the aggravation of intestinal inflammation, 
disease activity, and relapsing episodes (22). Through genetic 
analyses, it was shown that CD has more genetic components 
(such as loci associated with susceptibility to the disease) than 
does UC (21). Therefore, a better knowledge of the genetic 
variables and their interaction with environmental factors will 
generate a breakthrough in pharmacogenomics, which could be 
used as a treatment for the disease, improving the tolerability and 
effectiveness of the therapies used nowadays (21).
CONTRiBUTiON OF THe iNTeSTiNAL 
ePiTHeLiAL BARRieR TO BACTeRiAL 
iNFeCTiONS AND iBD DeveLOPMeNT
The intestinal epithelial barrier physically separates the intestinal 
lumen from deeper layers, such as the lamina propria (29). It 
is organized in crypts and villi and composed of four types of 
specialized cells: absorptive enterocytes that have metabolic and 
digestive functions and can also secrete some antimicrobial pep-
tides; goblet cells, specialized in mucus secretion; enteroendocrine 
cells that secrete hormones; and Paneth cells that mostly secrete 
antimicrobial peptides into the crypts of the small intestine 
(Figure 1A) (29). M cells, which are specialized follicle-associated 
epithelial cells that cover Peyer’s patches, are found in the small 
intestine. The function of these cells is sensing luminal content, a 
task required for the correct functioning of the epithelial barrier. 
Antigens and microbes captured by M cells are transported across 
the epithelial barrier and presented to immune cells residing in 
the lamina propria, through a process denominated transcytosis, 
which is essential for antigen-specific mucosal immune response 
(Figure 1A) (30).
Through the intestinal barrier, there are several proteins 
that monitor the environment of the intestinal lumen. Pattern-
recognition receptors (PRRs), for instance, are proteins expressed 
by different type of innate immune cells located in the intestinal 
tissue, such as dendritic cells, phagocytic macrophage and 
FigURe 1 | Normal intestinal epithelium versus altered intestinal epithelium observed in inflammatory bowel disease (iBD). (A) The normal intestine 
presents a high secretion of bactericidal molecules (defensins, REGIIIγ, and IgA) as mechanisms of defense against pathogenic bacteria. The commensal microbiota 
inhibits the access of pathogens to the epithelial barrier by competing for nutrients, maintaining homeostasis of the epithelial barrier, and supporting the host 
immune response. The commensal microbiota is composed of mainly Firmicutes and Bacteroidetes, and a lower percentage of Proteobacteria and Actinobacteria. 
They promote the secretion of mucus and antimicrobial peptides [short-chain fatty acid (SCFA), H2S] and the activation of some pathway of immune system such as 
the activation of macrophages and dendritic cells in lamina propria, and the production of cytokines such as IL-6, IL-23, and IL-12, which activates Th1 or Th17 
cells to produce cytokines acting on intestinal epithelium. (B) The intestine of IBD patient has a deregulated response to commensal microbiota by a decrease in the 
secretion of antimicrobial peptides such as α-defensins and increase in REGIIIγ as compensatory effect; these effects have relation with defect in Paneth and goblet 
cells. IBD patients showed lower Firmicutes and Bacteroidetes but have increased amounts of Proteobacterias resulting in a decrease production of SCFA, mucus, 
and increased inflammation. The epithelium produces an abnormal amount of IgG against commensal microbiota instead IgA. Macrophages produce higher 
amounts of cytokines that overstimulate Th1 or Th17 cells, which secrete pro-inflammatory cytokines to epithelium.
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granulocytes, cytotoxic natural killer, and γδ-T cells; as well 
as intestinal epithelial cells. PRRs sense pathogens through 
pathogen-associated molecular patterns (PAMPs), such as LPS 
or flagellin (31, 32). PRRs also have a role in the regulation of 
intestinal epithelial barrier, repair, and immune homeostasis (33, 
34). The PRRs include different type of members: toll-like recep-
tors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors 
(RLRs), and C-type lectin receptors (35, 36). RLRs and C-type 
lectin receptors are mainly involved in viral and fungal recogni-
tion, respectively (35). TLRs are present in the surface of epithelial 
cells and endosomes, and even some can be found inside Paneth 
cells or enteroendocrine cell (35). TLRs are distributed in differ-
ent portions of the intestine and differentially expressed on the 
apical or basolateral side of the cell. Then, the same PRR may 
respond differentially depending on its localization. For instance, 
TLR5 only produces an inflammatory response if it binds flagellin 
in the basolateral surface of the epithelial barrier, which involves 
the transcription of pro-inflammatory cytokines (37). Other 
proteins involved in pathogen recognition at the intestine are 
NLRs, which are found in the cytosol of macrophages, dendritic 
cells, and Paneth cells. These intracellular proteins sense PAMPs 
as well as endogenous molecules released from damaged cells, 
called damage-associated molecular patterns. NLRs can sense a 
distinctive substructure from peptidoglycan of mostly all Gram-
negative and Gram-positive bacteria (35, 38). Among the NLRs, 
NOD1 and NOD2 are the most studied. Both recognize products 
released by division of intracellular bacteria and, after NOD2 is 
activated, NF-κB translocates to the nucleus and allows the pro-
duction of IL-6, IL-1β, and TNF-α, to trigger a pro-inflammatory 
response (39).
M cells have another type of receptor, the glycoprotein-2 
receptor (GP2), which is found in the apical side of epithelial 
barrier and serves as transcytosis receptor for many antigens 
derived from commensal and pathogenic bacteria. This endo-
cytic receptor recognizes FimH, a component of type I pilus of 
diverse enterobacteria, such as Escherichia coli and Salmonella 
Typhimurium. GP2 interacts with bacterial pilus proteins, allow-
ing the capture of the bacterium by the cell and its transport 
across the barrier to the Peyer’s patches and other gut-associated 
lymphoid tissues (29, 30).
Another important component of the intestinal barrier is a 
wide assortment of resident microbial communities that prevent 
infection by competing with pathogenic bacteria. For example, 
commensal bacteria produce secondary metabolites that spe-
cifically inhibit members of the same or similar species able to 
cause infection. It has been shown that there are two bacterial 
phyla that predominantly reside in the gut of healthy individuals; 
these are Bacteroidetes (Gram-negative) and Firmicutes (Gram-
positive) (40). It has been reported that microbial communities 
may change due to age, nutrition, inflammatory processes, and 
gastrointestinal disease (Figure 1A) (41), and it has been dem-
onstrated that the presence of commensal microbiota induces a 
basal expression of certain TLRs (such as TLR2 and TLR5), as 
compared to the basal levels of expression observed in specific-
pathogen free mice and germ free mice (42). The same report 
shows that microbiota is essential to trigger a proper inflam-
matory response to infection by some pathogenic bacteria (42). 
Thus, a complex interplay between the host immune system and 
the microbiota is required for gut microbiota homeostasis. For 
instance, the production of IL-6 and TNF-α is triggered by com-
mensal microbiota, and a proper functioning of TLR is required 
for protection against injuries of the intestinal epithelium. Thus, 
it is possible that the use of antibiotics in pharmacological dose 
could impair the production of these cytokines due to a reduc-
tion of commensal microbiota, which in turn might result in a 
reduced tissue repair ability (33).
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A defect in the functioning of any of the epithelial barrier 
components mentioned above leads to an aberrant inflammatory 
response and promotes susceptibility to some diseases, such as 
IBD. In this case, it is known that defects in the response of goblet 
and/or Paneth cells generate a type of colitis or a spontaneous 
inflammation that resembles CD (29). Further, the dual role of 
TLRs could be also an important factor in the development of 
the disease (33, 42, 43).
DeFeCTS iN THe iMMUNe ReSPONSe TO 
BACTeRiAL PATHOgeNS AND 
MiCROBiOTA DeSCRiBeD iN iBD 
PATieNTS
As discussed above, the gut is constantly exposed to commensal 
microbiota and foreign microorganisms introduced by food 
consumption. The immune system helps to keep the correct 
homeostasis between the immunosuppressive response—which 
prevents overreaction to harmless antigens—and the protec-
tive response against pathogens (44). Intestinal tissue is highly 
deteriorated in IBD patients, especially in CD patients, due to 
an uncontrolled reaction of the immune system against bacterial 
antigens (44, 45). Thus, the epithelium is highly affected, and a 
pro-inflammatory response results in a loss of tolerance to the 
normal microbiota (Figure 1B) (45).
Several alterations in mechanisms of epithelial barrier protec-
tion are related to the pathology of patients with IBD, because a 
barrier dysfunction leads to impaired immune responsiveness, 
as in this disease. One of them is, for example, the secretion of 
mucus by goblet cells. IBD patients have decreased production 
and secretion of mucin-2, the main component of the mucus, 
which is related to the development of inflammation (46). This 
leads to a decreased protection of the epithelial barrier and a 
greater number of bacteria that are in direct contact with the 
epithelium (46, 47). Accordingly, mice lacking the gene encoding 
Muc2 (Muc2−/−) have increased gut inflammation and weight 
loss, and this deficiency could contribute to the onset and per-
petuation of the colitis. Beside this, it is important to mention that 
the microbiota has an important role in regulating the secretion 
of colonic mucus (46, 48).
The process of epithelial regeneration after an injury is also 
affected in IBD patients. Epithelial repair processes are divided 
in two phases: the first one involves the re-distribution of the 
existing cells, a process that is regulated by TGF-β. In the second 
phase, cell proliferation is regulated by cytokines such as IL-6, 
secreted by pro-inflammatory lymphocytes (27). TGF-β levels 
are increased in active UC and CD patients, relative to control 
patients, due to a constant inflammatory process and injury of 
the epithelial barrier that must be repaired (49). IL-6 is induced 
early after injury, allowing proliferation of intestinal epithelial 
cells that is needed for a proper healing of the epithelium but 
also has functionality in tumorigenesis and chronic inflam-
mation. These functions may be related to the development of 
cancer in IBD patient, having a central role in the pathophysi-
ology of the disease (50–52). Although the blockage of these 
pathways did not improve the histopathological score, it does 
improve disease activity score, and it may have a therapeutic 
potential (53).
As previously discussed, the epithelial barrier must be 
functional and not allow the entry of pathogens to the inner 
layers. If the tight junctions are altered, the permeability of the 
barrier could increase and, along with this, there will be a greater 
paracellular flow of microorganisms, promoting the infection 
of the lamina propria with pathogenic and/or opportunistic 
bacteria (54). It has been described that both TNF-α and IFN-γ 
can modify these junction structures, and it is known that IBD 
patients have an elevated production of TNF-α, which could be 
mediating the increased permeability due to the loss of tight 
junctions structure (54). However, it is not well understood if 
this dysfunction is a consequence of increased inflammation 
during an active disease or if it is the cause of IBD development, 
because some susceptible patients without symptoms or those 
in remission also show altered intestinal permeability (55). In 
normal conditions, the intestine is the major antibody producer 
tissue of the body, and the intestinal mucous membrane contains 
more than 80% of the activated B cells (56). IBD patients have a 
dysfunction in the B cell response, which involves an abnormal 
mucosal secretion of IgG antibodies against commensal bacteria 
instead of the physiological secretion of IgA (Figure 1B) (57, 58). 
This overproduction causes an exacerbated pro-inflammatory 
response and injury in the epithelium, which is not observed in 
healthy individuals and may be relevant in the development of 
the disease (59). Further, IBD patients also present antibodies to 
self-antigens or cross-reactivity against several bacterial and fun-
gal antigens, which often precedes the onset of the disease (60). 
For example, CD patients have antibodies against Saccharomyces 
cerevisiae (ASCA), E. coli, Pseudomonas fluorescens, and flagellin 
(61), which are directly related to the aggravation of the disease. 
Overreaction to these bacterial antigens generates additional 
clinical manifestations, such as stenosis and internal perforations.
eFFeCT OF ANTiBiOTiC TReATMeNT iN 
iBD PATieNTS
Inflammatory bowel disease is characterized by an augmented 
bacterial density at the mucosal level (62, 63), as well a dimin-
ished number of anti-inflammatory commensal bacteria, such 
as the Gram-positives Firmicutes and Actinobacteria (56, 64). 
As a consequence of this dysbiosis (dysregulation of commensal 
microbiota), an increased number of potentially harmful bacteria 
(such as Enterobacteriaceae) can occur, producing inflammation 
(65). For these reasons, maintaining a proper ratio of these popu-
lations is highly relevant, because they constitute a barrier against 
pathogenic bacteria (56). In support of this idea, studies have 
shown that UC patients, even in remission, have dysbiosis when 
compared to controls, with increased numbers of opportunistic 
pathogens such as Campylobacter spp. and Helicobacter spp. (66, 
67). Further, these patients show a reduction in the number of 
the cluster related to the metabolism of short-chain fatty acids 
(SCFAs), which generates less anti-inflammatory environment 
in their guts (66). For these reasons, the use of antibiotic in 
IBD patients to treat septic complication, such as abscesses and 
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wound infection, is still conflicting because it decreases the 
number of intestinal bacteria and alters the normal composition 
of the microbiota (68). Moreover, treatment with antibiotics 
increases the susceptibility of the patient to acquire an infection 
by Clostridium difficile (68, 69).
Along the same line, some studies have shown that antibiotic 
therapy is functional in UC and in CD, and the therapy works 
better if given orally. Two meta-analysis supports the role of the 
antibiotics in induction of the remission of IBD (70), specifi-
cally UC (71). This observation agrees with a study performed 
in some pediatric patients with severe refractory UC, where the 
children receive a triple therapy for 2–3 weeks with amoxicillin, 
metronidazole, and doxycycline in children over 7 years of age. 
This study shows that the treatment induced remission in 47% of 
the patients and the effects observed depend on the physiological 
characteristics of the patients and the current treatment used to 
ameliorate the symptoms (69). A systematic review shows that the 
induction of remission can occur in both CD and UC patients, 
but that is still not sufficient information to recommend a type 
or a cocktail of antibiotic to treat effectively the disease (72). In 
summary, most of the processes described above, which can pro-
mote the onset and severity of IBD, are related to proper bacterial 
location and clearance in the intestine. In the next section, we will 
discuss how pathogenic bacterial infection could trigger IBD in 
susceptible individuals.
Salmonella enterica iNFeCTiON AND iBD
Many pathogenic microorganisms have been implicated in the 
exacerbation or development of IBD (73): Campylobacter (1), E. 
coli (74), Helicobacter pylori (75), Mycobacterium avium subspe-
cies paratuberculosis (76), and C. difficile (77). We will focus on S. 
enterica serovar Typhimurium (1).
Salmonella enterica serovar Typhimurium (S. Typhimurium) 
is a facultative, Gram-negative and intracellular bacterium, which 
infects several host including humans (78). S. Typhimurium can 
cause a severe inflammation of the intestinal mucosal epithelium, 
resulting in humans, gastroenteritis, and in mice, typhoid-like 
systemic illness (78). As every pathogen, S. Typhimurium 
has several virulence genes, located in at least five Salmonella 
pathogenicity islands (SPIs), which are genetic elements within 
the Salmonella chromosome that was acquired probably by hori-
zontal gene transfer (79). The most important and more studied 
SPIs are SPI-1 and SPI-2. Both SPIs encode type III secretion 
systems (T3SS). These are complex machineries formed by more 
than 20 proteins that allow contact-dependent translocation of 
a set of different effector proteins into the eukaryotic cytoplasm 
(80, 81). SPI-1 allows Salmonella to invade epithelial cells, while 
SPI-2 allows the survival and replication inside phagocytic cells 
(79, 82).
The first step in S. Typhimurium infection is to cross the intes-
tinal epithelial barrier, which can be accomplished through four 
different routes (83, 84). The main route is through the activation 
of virulence factors encoded in SPI-1. A second route of inva-
sion requires the rupture of tight junctions of the epithelial cells, 
which changes the basal permeability of the intestinal barrier 
(85). Finally, there is another entry through CX3CR1+ DCs (86) 
interleaved in the epithelial barrier, reaching the bloodstream to 
spread to extraintestinal sites, through the transport in CD18+ 
phagocytes (87).
The second step in the cycle of infection of S. Typhimurium 
is the expression of T3SS-2 inside immune cells, such as mac-
rophages and DCs of the Peyer’s patches and lamina propria (88), 
in which this bacterium can survive and replicate within a specific 
compartment known as Salmonella-containing vacuole (SCV), 
which avoids lysosomal degradation and antigen presentation 
(83, 84). This initial invasion of the Peyer’s patches leads to an 
inflammatory response with recruitment of immune cells, mainly 
neutrophils, which should prevent bacterial dissemination 
(Figure 2D).
iMMUNe ReSPONSe AgAiNST Salmonella
Commensal microbiota, mucus layers, antimicrobial peptides, 
and tight junctions work together to maintain the integrity of the 
epithelial cellular barrier and prevent infection of pathogenic bac-
teria (89). Despite all these defense mechanisms, S. Typhimurium 
can modify tight junctions to increase the permeability of the 
barrier, which allows its translocation through the epithelial cell 
monolayer, due to the secretion of a protein-denominated AvrA 
through the T3SS-1 (85). This protein impaired the activation 
of pro-inflammatory cytokine, such as IL-6 (90) and can affect 
cellular proliferation activating the β-catenin pathway (91). 
Beside this, AvrA can modulate the c-Jun N-terminal kinase, 
which suppresses the apoptosis process during early steps of the 
infectious process (92). All these mechanisms together allow S. 
Typhimurium to produce inflammation of the intestine, without 
destroying the epithelium.
Toll-like receptors and NLRs recognize various compounds 
of S. Typhimurium, activating pathways associated with a pro-
inflammatory response such as pyroptosis, which is a cell death 
response that involves the production of caspase-1, required for 
the secretion of mature IL-1β and IL-18 by macrophages (93, 94). 
For example, flagellin is recognized by TLR5 in the basolateral 
surface (30, 32, 37), which actively promotes the production of 
pro-inflammatory cytokines, such as IL-6 (95) and IL-8 (96), 
through the activation of the transcription factor NF-κB and MAP 
kinases, followed by the recruitment of inflammatory cells and the 
activation of the adaptive immune response. Although immune 
cells rapidly clear bacteria, an important fraction disseminates to 
deeper organs using phagocytic cells as a “Trojan horse.” Using 
this mechanism, S. Typhimurium can migrate from the site of 
infection to the lymph nodes and activate T cells (97). In addi-
tion, S. Typhimurium can induce the production of caspase-1 via 
Nlrc4 (a type of NLR) through the recognition of flagellin, which 
enters through the T3SS-1 to the cytosol of phagocytic cells. 
This cytosolic response is independent of the one generated by 
TLR5 (extracellular) (36). In this way, S. Typhimurium uses this 
defense mechanism (production of inflammasome and pyrop-
tosis process) to spread to other immune cells and disseminate 
systemically from the gastrointestinal tract (93).
During an infection with S. Typhimurium, the response of 
NOD1 or NOD2 occurs through the activation of the transcrip-
tion factor NF-κB, which has an important role in the regulation 
FigURe 2 | effect of Salmonella infection in inflammatory bowel disease (iBD) patients. In genetically susceptible to IBD patients, many parameters are 
disrupted. (A) Paneth cells have an impaired secretion of antimicrobial peptides showing a decrease in the amounts of α-defensins, as well as increased amounts of 
REGIIIγ, which is associated with impaired protection against pathogens. (B) Plasma cells have a polarized antibodies’ secretion to the production of IgG antibodies 
targeting the individual’s own microbiota. Beside this, the proportions of commensal microorganisms present are unbalanced related to a healthy host. Due to this 
imbalance, there is a decrease production of short-chain fatty acid (SCFA), which generates an increase in inflammation. Taken together, these effects generate an 
environment more vulnerable to further infection. Furthermore, (C) S. Typhimurium recruits neutrophils to the lumen, which generates ROS, producing tetrathionate 
in the intestinal lumen; this compound is used by Salmonella as electron acceptor, which gives advantage to S. Typhimurium over the microbiota. (D) Salmonella 
infection is produced by the entry through DCs interspersed in the epithelial barrier or M cells that recognize it through glycoprotein-2, accessing to the Peyer’s 
patches. (e) Salmonella can also get into the epithelial cells forming membrane ruffling or through disruptions of tight junctions caused by itself and in this case 
especially in inflamed epithelium of IBD patients. (F) In the basolateral side, Salmonella can be recognized by TLR5 stimulating an increased production of NF-κβ, 
which correlates with an enhanced recruitment of neutrophils, finally once within the epithelial cells, Salmonella blocks the autophagosome pathway avoiding its own 
degradation.
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of cytokine production. Thereby, it modulates the transmigration 
of neutrophils to the source of infection and thus the intensity of 
the inflammation (Figure 2F). The activation of another signaling 
cascade via NOD2, triggered also by MDP, has a direct relation 
with the activation of the inflammasome NLRP3 through NF-κB, 
caspase-1, and the consequent secretion of IL-1β and IL-18 (98, 
99). The correct function of these receptors is important, because 
through its activation they interact directly with the ATG16L1 
protein and lead to the proper initiation of the autophagy process 
(99, 100).
All these effects produce an increase in inflammation after 
bacterial infection because of the structure loss of the intestinal 
mucosa, producing diarrhea with concomitant loss of liquid 
and electrolytes (97). This response against foreign microorgan-
isms must be controlled to reduce tissue damage or to prevent 
a systemic infection, as it could be the case of S. Typhimurium 
(Figure 2B). However, sometimes the immune response is altered 
and generates an overreaction against its own components, as in 
the case of IBD.
Salmonella iNTeRACTiON wiTH 
MiCROBiOTA
Commensal microbiota is mostly fermentative and produces 
at least three SCFAs, which are mainly acetate, propionate, and 
butyrate (101). The concentration and distribution of these 
compounds vary along the gut and exert different effects on 
colonization of pathogenic bacteria, such as Salmonella. In the 
ileum, there are higher concentrations of acetate, which induce 
the expression of genes within SPI-1, allowing the invasion of 
the ileum (101). Moreover, propionate and butyrate are present 
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in higher amounts in colon and cecum (102) playing an antimi-
crobial effect, diminishing the expression of the same invasion 
genes (101–103). Therefore, SCFAs produced by the microbiota 
influence S. Typhimurium’s “choice” of the site of colonization, 
and given that any change in the composition of the microbiota 
will vary the proportion of these compounds, they could allow for 
a different disease phenotype.
S. Typhimurium infection produces the transmigration of 
neutrophils, which oxidize the endogen sulfur compound thio-
sulfate S O2 3
2−( ) in the intestinal lumen, generating tetrathionate 
S O4 6
2−( ) (Figure  2C) (104, 105). This product is an electron 
acceptor for S. Typhimurium energetic processes and allows 
the utilization of ethanolamine as a nutrient by the bacterium. 
This is a competitive advantage over the fermentative bacteria 
from the microbiota, which are unable to use this product, so 
S. Typhimurium will overgrow and disseminate (41, 105, 106). 
Beside this, neutrophils induce the change of microbiota during 
an infection with S. Typhimurium secreting a serine protease 
(elastase), which has a direct effect to the microbiota (107). 
This way, S. Typhimurium used both the inflammation and the 
secretion of elastase to create a more favorable environment 
for its own colonization. S. Typhimurium can take advantage 
of the inflammatory response and promote its own growth and 
dissemination into host tissues. Moreover, this pathogen could 
play an important role in changing the microbiota composition 
in genetic susceptible individuals or patients with a chronic 
inflammation, such as IBD, due to mainly the dysbiosis in these 
patients (41, 108).
S. Typhimurium iNFeCTiON: PReviOUS 
OR AFTeR iBD ONSeT?
In this section, we will discuss some factors that could relate the 
intestinal inflammation that occurs in IBD and the intestinal 
infection caused by S. Typhimurium (Figure 2). A previous study 
suggests a connection between S. Typhimurium infection and 
IBD development (1). Furthermore, another study describes the 
presence of Salmonella and other enteropathogen toxins in the 
serum of IBD patients, which correlates to disease progression 
(109). However, a following study in Danish population sug-
gested that increased detection of Salmonella and Campylobacter 
in stools of IBD patients is due to detection bias during the first 
year of infection (110). Although no association of exposure 
to S. enterica in CD patients was observed in a study made in 
another cohort of patient, a relation between CD, cigarette 
smoking, and anti-Salmonella antibodies in serum was observed 
(111). However, some studies suggest that during the course of 
IBD, due to the dysbiosis of the disease itself, the chances of an 
infection by enteropathogens are higher (108, 112). Other studies 
showing positive results with antibiotics treatment of IBD suggest 
the possibility of a pathogenic agent as the causative agent of the 
disease (72).
The permeability of the epithelium in IBD patients is altered 
and allows increased transcytosis of commensal and/or patho-
genic bacteria, which could generate an inflammatory response. 
When an infection with an invasive bacterial pathogen (such as 
S. Typhimurium) occurs, it generates the recognition by basolateral 
TLR5 (Figures 2E,F), which initiates an inflammatory immune 
response (37). It has been shown that the signaling through TLR5 
after flagellin recognition in a murine model of chemical-induced 
colitis generates an increase in the secretion of pro-inflammatory 
cytokines (32, 96) such as IL-8, which recruits neutrophils to 
the site of infection (113) and aggravates the clinical symptoms, 
producing severe histopathological damage in the colonic 
mucosa (32). Therefore, IBD patients can be more susceptible to 
an infection with a pathogen as S. Typhimurium, which could 
trigger the onset or aggravate the course of the disease, leading 
to a relapse. Additionally, S. Typhimurium synthesizes FimH, a 
protein that binds to M cells by interacting with GP2. GP2 has 
an epitope recognized by “anti-pancreatic” antibodies found in 
CD patients (114), which could be a consequence of infection 
with this pathogen or could involve the need for the combination 
between the receptor and FimH to produce antibodies.
A deregulation of the secretory function of Paneth cells has 
been observed in IBD patients. For instance, CD patients have 
diminished production of α-defensins at both mRNA and protein 
levels. Further, IBD patients have also an augmented secretion 
of Reg-lectin family members, such as RegIIIγ, which has a 
compensatory effect in the decrease in α-defensins (Figure 2A). 
This phenomenon is related to the increased adherence of the 
commensal microbiota to the enteric mucosa and an augmented 
penetration of the commensal bacteria to the mesenteric lymph 
nodes, which generates an inflammatory environment (115). 
All these impaired processes are being observed in the ileum of 
affected IBD patients and are more pronounced in individuals 
that also carry mutations in the nod2 gene. However, these defects 
per se are not translated in increased inflammation of the intes-
tine, which suggests that an additional trigger (such as bacterial 
infection) may promote IBD in these susceptible patients (116, 
117). A recent study has described that the polymorphism T300A 
in the gene atg16l1 results in a defective production of C-type 
lectin domain family 12 member A (CLEC12A) in CD patients, a 
protein potentially involved in antibacterial autophagy (118). This 
study shows that absence of CLEC12A prevents S. Typhimurium 
clearance by HeLa cells and that mice lacking CLEC12A are more 
susceptible to suffer a more severe infection (118). As mentioned 
above, mutations in the atg16l1 gene also alter the function of 
Paneth cells due to changes in the granule exocytosis pathway 
(26). In the same context, S. Typhimurium diminishes the 
granules production and the secretion of lysozymes by Paneth 
cells, through the activation of p38/MAPK in the small intestine 
(117). This could be a survival mechanism of the bacterium and 
may be required by the subsequent infection process. Beside this, 
the infection activates a differentiation program that results in 
hyperplasia of Paneth cells in crypts, which could give as a result 
an acute inflammatory response and have some effect in the 
intestinal stem cells, due to an accelerated process of proliferation 
(119). Further, S. Typhimurium generates hyperplasia of Paneth 
cells through the activation of the Wnt pathway, but IBD patients 
have deficiencies in different factors (such as Tcf4, for example) 
of the same pathway, which is related to decrease the secretion 
of α-defensin (120) (Figure 2A). The combination of virulence 
factors displayed by S. Typhimurium and the genetic alterations 
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of the host that prevent correct bacterial clearance suggests that 
an infection with S. Typhimurium in a susceptible host could gen-
erate changes in the proliferation and differentiation of Paneth 
cells, which in patients suffering IBD will exacerbate the defect 
produced by the mutation in some of the genes related to this 
pathology, which finally will modify the lysozyme secretion, with 
a consequent alteration in microbiota. All these changes generate 
a new or different niche to the infection and finally the onset of 
the disease with possible different phenotypes.
Other important factor related to IBD and S. Typhimurium 
infection is the formation of autophagosomes. S. Typhimurium 
survives inside the SCV without being recognized by the host 
cell. However, if this compartment is damaged, ubiquitination 
can modify the bacterium, leading to its autophagy encapsu-
lation. Despite this, Ssel, a soluble protein secreted by T3SS, 
actively deubiquitinates the bacterium to prevent formation of 
the autophagosome (121). In this context, the intestinal epithe-
lium responds to a S. Typhimurium infection with increased 
secretion of factors related to the autophagosome formation 
(121). Therefore, the activation of this pathway is one of the 
main processes required for resolution of the infection caused 
by this intracellular bacterium. In IBD patients, there are three 
genes related to the autophagosome process that are affected: 
irgm, nod2, and atg16l1, each associated with different grades 
of susceptibility to suffer IBD, which implies a defect in antigen 
uptake and its processing, the interaction between dendritic 
cells and intestinal epithelial cell (45), and the regulation 
of PRRs and inflammasome activation. These genes encode 
proteins that are important to contain the infection caused by 
S. Typhimurium (122).
Mutations in the atg16l1 gene generate defects in the formation 
of autophagosomes, which implies that lower numbers of bacteria 
will be captured and so less efficient bacterial clearance will occur 
(121, 123). Beside this, patients with CD that carries an atg16l1 
mutation (45) have an impaired degradation of S. Typhimurium, 
making the host more susceptible to the infection. NOD2 is 
required for the formation and activation of the phagosome 
and for the recruitment of ATG16L1 to the site of entry of the 
bacterium, therefore mutations in this gene generate lower levels 
of autophagy and an impaired bacterial clearance (100). Mutation 
in the atg16l1 gene impaired the correct antibacterial function 
of NOD2 in epithelial cells of the colon, and mutation in nod2 
generates an impaired signaling and bacterial killing, but this 
mutation only partially affects the autophagy process (124). So, 
in this case, an infection by S. Typhimurium in a susceptible host 
could be more severe, as proper function of the above mentioned 
proteins is required for the correct bacterial clearance and for the 
control of dissemination of S. Typhimurium to extraintestinal 
sites, and this is not necessarily related to the anticipated develop-
ment of the disease, but it is possible that all these factors could 
allow the bacteria to survive longer inside the cells and generate 
an inflammatory atmosphere that promotes the onset of IBD.
Some studies have demonstrated that MDP induces autophagy 
in dendritic cells, a process that needs correct NOD2 signaling, 
which in turn requires mainly the proper function of ATG16L1. 
These proteins are required for the correct function of NOD2 
and antigen presentation (125). Mutation in this gene generates 
a malfunction in the autophagy process in dendritic cells, which 
indicates an aberrant bacterial trafficking and failure to produce 
antigen presentation on MHC-II molecules, which in turns 
promote the generation of antigen-specific, effector CD4+ T cells 
(125). All these defects may allow bacteria to survive longer inside 
dendritic cells, avoiding lysosomal degradation for extended time 
(126, 127) and to provide a mechanism for the persistence of 
the pathogen and in consequence the persistent inflammation. 
Beside this, it has been reported that S. Typhimurium employs 
dendritic cells expressing CCR7 as a pathway to migrate from the 
intestine to MLNs (127).
The above background suggests that during an infection with 
S. Typhimurium, the bacterial virulence factors and the defec-
tive processes in susceptible individuals, such as those described 
in IBD patients, could generate a persistence of the bacteria in 
dendritic cells, which would generate a continuous secretion 
of pro-inflammatory cytokines and an environment of inflam-
mation, which means that an infection with S. Typhimurium in 
these patients could have a double effect, being more permissive 
to the infection caused by this intracellular bacteria. Because of 
this, we propose that an infection with S. Typhimurium could 
anticipate the onset of the disease, due to the atmosphere of 
inflammation that it generates. Furthermore, the infection with 
S. Typhimurium changes the composition of the microbiota and 
the permeability of the epithelial barrier, which could be a trigger 
for the disease in susceptible individuals, given that these changes 
modify the production of cytokines and SCFAs, produce an influx 
of neutrophils and persistence infection of dendritic cells and, 
in consequence, generate an abnormal inflammatory environ-
ment. All this, combined with a genetic susceptibility, will impair 
the recognition of pathogens, the autophagy, tissue repair, and 
bacterial clearance, generating an inflammatory condition at the 
intestinal epithelium.
CONCLUDiNg ReMARKS
In this review, we discussed several microbial, cellular, and 
genetic alterations described so far in IBD patients, and related 
these defects with the infection caused by S. Typhimurium. It is 
possible that S. Typhimurium infection could trigger chronic 
inflammation in individual carrying one or more of the defects 
associated with IBD, given the inability of these patients to prop-
erly clear bacteria in the intestine. Moreover, S. Typhimurium 
has an important arsenal of virulence factors to invade host cells 
in the intestinal epithelium and lamina propria that the normal 
microbiota is not able to reach. Additionally, it is known that this 
bacterium can cause persistent infection in human and in mice, 
suggesting that in patients displaying one or more genetic defects 
that predispose to IBD development; it is possible that they are 
much more susceptible to be infected by S. Typhimurium and 
cause a persistent infection. Permanent infection of cell with S. 
Typhimurium could promote secretion of pro-inflammatory 
cytokines by infected cells, generating an inflammatory environ-
ment in the intestinal layers, promoting changes in the microbiota 
and promoting chronic diseases. It would be relevant to evaluate 
whether IBD patients are chronic carriers of S. Typhimurium in 
the intestine.
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Supporting the hypothesis raised in this review, it has been 
described that IBD patients have a deregulated immune response 
in the intestine, which is reflected for instance by the secretion 
of IgG instead of IgA, resulting in an inflammatory response 
against their own microbiota (56). This loss of tolerance to the 
microbiota could be determining factor to the infection with an 
invasive bacterium as S. Typhimurium, which could promote a 
permanent inflammatory response in the intestine, which in turn 
could bias the humoral immune response to an IgG type to other 
bacteria, as the intestinal microflora. It has been described that in 
IBD patients the commensal microbiota has different phyla pro-
portions in comparison to a healthy person, having less amount 
of Bacteroidetes and Firmicutes (beneficial bacteria) (56, 66, 67). 
This allows less competition to pathogenic bacteria, making them 
more invasive. On the other hand, in these patients, the epithelial 
barrier is impaired because of inflamed epithelial cells, continu-
ous secretion of pro-inflammatory cytokines, and disrupted tight 
junctions (54). It is possible that all these alterations could be 
due to S. Typhimurium infection, which results in an increased 
inflammation in susceptible patients (44, 46, 54).
It is known that S. Typhimurium can produce an inflamma-
tory environment due to virulence proteins coded by SPIs, which 
improve its fitness over intestinal microbiota and, thereby, to 
reach and invade the epithelium (79). Therefore, the inflamma-
tion would not be detrimental for this kind of invasive pathogen 
and conversely it might be facilitating growth (41, 89, 128, 
129). Even more, it is possible that through this mechanism, S. 
Typhimurium can accelerate the development of the disease in 
people with genetic susceptibility. Due to the factors mentioned 
above, it is possible that in IBD patients will be more susceptible 
to suffer a more aggressive infection by S. Typhimurium or even 
to develop a persistent infection, due to the baseline inflamma-
tion and impaired intestinal environment. Therefore, the devel-
opment of new methods that could prevent early colonization 
with this pathogen in this type of patients is a challenge for future 
research.
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